Press Detail

PRESS RELEASE

Biotest stock split becomes effective as scheduled - first trading day on July 15

- Stock listing and shareholders' deposits will be changed on July 15th in a ratio 1:3

- Shares in security accounts will be converted automatically

- Unexecuted orders will expire after July 14

Dreieich, 14 July 2015. The stock split with capital increase from company funds was recorded in the commercial register on 22 June, 2015. After close of trading today, shareholders' deposits and the stock exchange listing will be converted. Trading at the new split-adjusted price will start tomorrow, July 15, 2015.

Biotest AG shares will continue to trade under ISIN DE0005227201 (ordinary shares) and ISIN DE0005227235 (preference shares).

The subscribed capital of Biotest AG now amounts to EUR 39,571,452 divided into 19,785,726 ordinary shares and 19,785,726 preference shares.

Every shareholder will receive two additional shares for each share held. With the stock split, Biotest aims to promote trading activity and increase the stock's attractiveness for a broader group of investors.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2,100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
Tel.: +49 (0) 6103 801-4406,
email: investor_relations@biotest.de

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart